Uber Expands Autonomous Services with Waymo and Cruise Partnerships

Published 8 hours agoUBER

Uber Expands Autonomous Services with Waymo and Cruise Partnerships

Uber is ramping up its autonomous ride-hailing efforts in Texas, although no partnership with May Mobility has been confirmed for the state. The company has been making significant strides through collaborations with other leading autonomous technology firms, expanding its reach and capabilities within the region.

In a notable expansion, Uber joined forces with Waymo in September 2024 to bring autonomous ride-hailing to Austin and Atlanta, starting in early 2025. The partnership will see Waymo's all-electric Jaguar I-PACE vehicles integrated into the Uber app, offering a fully autonomous riding experience. Moreover, Uber has also inked a multiyear strategic partnership with Cruise, a subsidiary of General Motors, to include self-driving cars in Uber's offerings starting this year in an undisclosed city. These partnerships emphasize Uber's dedication to growing its autonomous vehicle service portfolio. Reuters reported these developments as a significant step in Uber's strategy to integrate cutting-edge technology into everyday urban mobility.

While May Mobility has been running autonomous vehicles as part of a publicly funded program in Arlington, Texas since 2021, there has been no confirmed deal with Uber in Texas. However, Uber's recent collaborations reflect a strategic move to solidify its position in the burgeoning autonomous vehicle market. The company's continued focus on partnerships with major players in the field highlights its commitment to expanding autonomous ride-hailing services and leveraging next-generation transportation solutions.

Share this article

Twitter Facebook LinkedIn

Recent Articles

iRhythm Technologies Aims for $685 Million Revenue by 2025

iRhythm Technologies Aims for $685 Million Revenue by 2025

26 minutes agoIRTC

iRhythm Technologies has set a bold revenue target of $675 million to $685 million for 2025, as announced during its recent financial update. The company is focusing on expanding its reach in the healthcare sector through various strategic initiatives. One key strategy is targeting primary care physicians, which in 2023 accounted for about 21% of new U.S. Zio XT and Zio monitor registrations. Additionally, the company's Zio AT technology has advanced with FDA clearance for two 510(k) submissions, enhancing its capabilities. Reuters highlighted iRhythm's efforts to expand internationally, with ventures in four European countries, gaining Japanese regulatory approval, and forging a strategic partnership with BioIntelliSense. iRhythm is also integrating its systems with Epic Aura, having launched four healthcare systems in the fourth quarter of 2024, with broader plans for 2025. Moreover, the company has begun shipments of Zio monitors for home enrollment patients, aiming to improve service accessibility. These strategies collectively underpin iRhythm's ambitious 2025 revenue aspirations.

Dexcom Unveils Plans for Extended Wear G7 Glucose Monitor in 2025

Dexcom Unveils Plans for Extended Wear G7 Glucose Monitor in 2025

41 minutes agoDXCM

Dexcom has announced its plans to launch a new 15-day continuous glucose monitoring (CGM) system, the G7, in the second half of 2025. This comes on the heels of a robust first-quarter performance where revenue hit $921 million, showcasing a 24% increase from the previous year. The uptick in revenue is attributed to the growing demand for the G7 CGM system, known for its accuracy and enhanced user experience, as well as the FDA's approval of the direct-to-watch feature for the G7 and Stelo, a glucose biosensor tailored for non-insulin-dependent type 2 diabetes, according to Investing.com. The upcoming 15-day G7 system is currently under FDA review, with its market debut expected to further bolster Dexcom's earnings and improve their gross margins. As more users switch to the sensor with a longer wear time, the company's financial outlook remains positive. Fool.com notes that this strategic move aligns with Dexcom's broader goal of expanding its footprint in the CGM market, positioned to benefit user experience and financial outcomes. Dexcom has revised its revenue projections for 2025, now forecasting between $4.20 billion to $4.35 billion in revenue, suggesting an organic growth rate of 17% to 21%. The company anticipates reaching total revenues of $4.6 billion, marking a 14% increase year-over-year. With these strategies and the new product launch, Dexcom is well-placed to maintain its growth trajectory within the competitive diabetes management arena.

Universal Display Unveils 2025 Revenue Outlook and Strategic Developments

Universal Display Unveils 2025 Revenue Outlook and Strategic Developments

56 minutes agoOLED

Universal Display Corporation (UDC) recently outlined its financial expectations for 2025, projecting revenues between $640 million and $700 million. This projection indicates a careful approach amid the evolving landscape of the OLED industry. Additionally, UDC has declared a first-quarter 2025 cash dividend of $0.45 per share, payable on March 31, 2025, to shareholders on record as of March 17, 2025. In other developments, Universal Display is advancing its work on blue phosphorescent OLED (PHOLED) materials, which, despite taking longer than anticipated, are expected to reach commercialization in the coming months. This progress is significant for the OLED field. Moreover, UDC is restructuring its operations by closing its California-based OVJP center and setting up a new subsidiary, Universal Vapor Jet Corporation, in Singapore. This new entity will focus on commercializing its Organic Vapor Jet Printing technology, as reported by oled-info.com. These strategic moves illustrate UDC's dedication to innovation and growth within the OLED market. By enhancing its material development and restructuring its operations for efficient technology commercialization, UDC aims to solidify its position in the competitive OLED sector.

Amgen Projects Strong 2025 Revenue Growth with Expanding Product Pipeline

Amgen Projects Strong 2025 Revenue Growth with Expanding Product Pipeline

1 hours agoAMGN

Amgen has recently projected robust revenue growth for 2025, forecasting total revenues between $34.3 billion and $35.7 billion with adjusted earnings per share ranging from $20.00 to $21.20. This positive outlook comes as the company continues to advance its extensive product pipeline and expand into new therapeutic areas. Key drivers influencing Amgen's anticipated growth include several innovative therapies. The cholesterol-lowering drug Repatha, osteoporosis treatment EVENITY, and severe asthma therapy TEZSPIRE are all expected to contribute significantly to Amgen’s revenue. Furthermore, the company's oncology portfolio, rare disease treatments, and the launch of new biosimilars should bolster earnings. According to longportapp.com, Amgen's biosimilar portfolio, in particular, experienced a 16% increase in 2024, contributing to its optimistic outlook. Amgen's strategic interests also reflect heavy investment in research and development, with a planned increase of approximately 15% in R&D spending year-over-year. The focus will be on advancing therapies like MariTide, an obesity treatment preparing for Phase 3 trials in early 2025, as mentioned by Amgen. Additionally, Amgen has announced a significant $900 million expansion of its biotech manufacturing facility in Ohio, a move that Reuters reports will generate 750 new jobs and increase its total investment in the region to over $1.4 billion.